Homepage084990 • KOSDAQ
add
Helixmith Co Ltd
Vorige slotkoers
â‚©Â 2.660,00
Dag-range
â‚©Â 2.540,00 - â‚©Â 2.680,00
Jaar-range
â‚©Â 2.115,00 - â‚©Â 4.950,00
Beurswaarde
118,69Â mld. KRW
Gem. volume
90,25K
Koers/winst
-
Dividendrendement
-
Primaire beurs
KOSDAQ
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (KRW) | dec 2024info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 1,63Â mld. | 203,14% |
Bedrijfskosten | 2,28Â mld. | -65,70% |
Netto inkomsten | -1,96Â mld. | 94,61% |
Netto winstmarge | -120,28 | 98,22% |
Winst per aandeel | — | — |
EBITDA | -280,49Â mln. | 92,01% |
Effectief belastingtarief | — | — |
Balans
Totale activa
Totale passiva
| (KRW) | dec 2024info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 76,11Â mld. | -33,22% |
Totale activa | 148,89Â mld. | -34,49% |
Totale passiva | 6,85Â mld. | -90,68% |
Totaal aandelenvermogen | 142,04 mld. | — |
Uitstaande aandelen | 46,05 mln. | — |
Koers-boekwaardeverhouding | 0,86 | — |
Rendement op activa | -2,10% | — |
Rendement op kapitaal | -2,19% | — |
Kasstroom
Nettomutatie in liquide middelen
| (KRW) | dec 2024info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | -1,96Â mld. | 94,61% |
Operationele kasstroom | -1,39Â mld. | 68,41% |
Kasstroom uit beleggingen | 1,38Â mld. | 111,33% |
Kasstroom uit financiering | -5,47Â mln. | -100,02% |
Nettomutatie in liquide middelen | -363,50Â mln. | -101,86% |
Vrije kasstroom | -2,04Â mld. | -104,61% |
Over
Helixmith Co. LTD. is a biotechnology company located in Seoul, South Korea with US presence in San Diego. The company has an extensive gene therapy pipeline, including a non-viral plasmid DNA program for neuromuscular and ischemic disease, a CAR-T program targeting several different types of solid tumors, and an AAV vector program targeting neuromuscular diseases. Helixmith’s lead gene is Engensis, currently in phase III diabetic peripheral neuropathy in the US. Engensis is a plasmid DNA designed to simultaneously express two isoforms of hepatocyte growth factor, HGF 728 and HGF 723. In addition to DPN, Engensis is also being studied in diabetic foot ulcers, amyotrophic lateral sclerosis, coronary artery disease, claudication, and Charcot-Marie-Tooth disease. Wikipedia
Opgericht
nov 1996
Website
Werknemers
72
